China’s MOH Sets Up Three New Departments To Oversee Food And Drugs
This article was originally published in PharmAsia News
Executive Summary
To tighten hospital supervision, food and drug safety, China's Ministry of Health has set up three departments for overseeing health care services, drug policy and the basic medicine system, as well as food safety coordination and hygiene. This follows responsibility changes between MOH and China's State FDA (PharmAsia News, Sep. 8, 2008). Under the framework, the new departments will (1) monitor health care institutions' services and promote public hospital management system reform; (2) establish and implement the national basic medicine system, as well as draw up the country's drug policy; and (3) draft standards for food safety and investigate major food safety incidents. Health authorities at the local level may decide on their own whether to undertake the corresponding changes. (Click here for more - Chinese Language)
You may also be interested in...
China To Step Up Supervision Of Human Organ Transplants; Enforce Ban On Foreigners Receiving Transplants
SHANGHAI - China's Ministry Of Health is set to extensively review hospitals already approved to provide human organ transplants nationwide, and will bar any other hospitals from facilitating transplants in the future, according to a report published on the ministry's official Web site
China’s Ministry Of Health To Specify Administration Responsibility
According to China's Ministry of Health, its proposed bill of determining function, organization structure and staff allocation has been approved by the State Council. This means MOH will now oversee State FDA. The adjustment is mainly in four aspects: MOH will administer SFDA and State Administration of Traditional Chinese Medicine; SFDA will transfer the responsibilities of overall coordination of food safety and major food safety incident inspection to MOH; a new healthcare service supervision bureau as well as bureau for pharmaceutical policy and national basic medicine system will be set up; and the responsibilities of relevant authorities on drug safety supervision will be clearly defined. (Click here for more - Chinese Language)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.